Home › Diffuse Large B-Cell Lymphoma › Tennessee › Nashville
Diffuse Large B-Cell Lymphoma clinical trials in Nashville, TN
17 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RecruitingPhase 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
- Henry-Joyce Cancer Clinic ( Site 0115), Nashville
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- SCRI Oncology Partners ( Site 7000), Nashville
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- SCRI Oncology Partners ( Site 7002), Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RecruitingPhase 2
- Tennessee Oncology, Nashville
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- SCRI Oncology Partners, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- TriStar BMT, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RecruitingPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- Vanderbilt University Medical Center, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- SCRI Oncology Partners, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- Tennessee Oncology, Nashville
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY20 studies
- Baldwin Park, CA19 studies
- Los Angeles, CA18 studies
- Houston, TX18 studies
- Chicago, IL18 studies
- Milwaukee, WI17 studies
- Boston, MA17 studies
- Philadelphia, PA15 studies
- Durham, NC15 studies
- Portland, OR15 studies
- Cleveland, OH13 studies
- Seattle, WA13 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer78 studies
- Metastatic Cancer69 studies
- Colorectal Cancer67 studies
- Cancer (all types)65 studies
- Ovarian Cancer50 studies
- Head and Neck Squamous Cell Carcinoma43 studies
- Prostate Cancer40 studies
- Pancreatic Cancer39 studies
- Lung Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.